\
&
Contact us
\
&
Contact us
Published on | 2 years ago
Programmes Horizon EuropeSeveral Hungarian universities are threatened to be cut off from Horizon Europe funding over ongoing concerns about rule of law breaches in the country, based on the Council Implementing Decision (EU) 2022/2506, effective as of 16 December 2022. The suspension, under the EU’s conditionality regulation affects institutions operated as ‘public trust foundations’ or maintained by such foundations. Science Business reported that the Hungarian government has brought 34 institutions under the control of these foundations since 2021 and has published a list of the concerned universities.
Hungarian entities concerned by the Council Implementing Decision can continue to apply to calls for proposals after 16 December 2022. For successfully evaluated proposals, if these measures are not lifted at the time of the grant agreement signature, the concerned Hungarian entities would be found ineligible to receive Union funding. These Hungarian entities could still participate without receiving EU funding, as associated partner, if allowed by the call conditions.
While the purpose of this decision is to protect the Union budget and not to exclude these entities from participation in Union programmes, the Commission has prepared a list of FAQs on how this decision affects their participation in Horizon Europe actions. It will be up-dated in reaction to further questions.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
